Beite pharmaceutical is the first in China to pass the consistency evaluation!

Great news! It is the first in China to pass the consistency evaluation! Before that, no manufacturers of cefixime oral series have passed the consistency evaluation, while Beite pharmaceutical industry, with its strong R & D strength, has taken the lead in the first review, which is a historic moment This time, we have experienced strict quality control According to the pharmaceutical research certification, the quality of the product is consistent with the original research It is also verified by clinical trials that the therapeutic effect of triponin ® is the same as that of the original study In addition, TPN ® has many excellent product characteristics, which are worthy of clinical promotion and application: * characteristics 1: TPN ® covers common pathogenic bacteria and has high sensitivity [1] * characteristics 2: TPN ® is recommended for community acquired infection guidelines [2] * characteristics 3: TPN ® has good clinical efficacy [1] The total effective rate of cefixime in the treatment of various bacterial infections (respiratory system, urogenital system and digestive system infection) was 90% - 100% in adults, children and children * trait 4: fewer adverse reactions of TPN [3] the adverse reactions of cefixime reported in literature are less, mainly rash and digestive system reactions The patients with rash stopped taking medicine immediately after the occurrence of allergic symptoms, recovered in a short time after symptomatic treatment, the digestive system reaction did not affect the treatment and medication of the patients, no other serious adverse reactions were reported In view of the above excellent product characteristics, cefixime has been widely used in more than 80 countries since it was launched in 1987 [1] According to the network data in 2017, the market capacity of cefixime oral products has exceeded 4 billion, and TPN ® is a class B national medical insurance drug, with a broad market prospect [reference] 1 Zhang Mingfa, et al Clinical research and evaluation of cefixime in China, anti infective pharmacy, 2010, 3, 7 (1): 1-9 2 Guiding principles for clinical application of antibacterial drugs (2015 Edition) 3 Yang Hui, clinical review and literature of cefixime tablets, scientific forum: 260